Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC).
Phase 2
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Device: LW-02 device immunopheresis combined with atezolizumabDevice: LW-02 device immunopheresis combined with weekly paclitaxelDevice: LW-02 device immunopheresis
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Immunicom Inc
- Target Recruit Count
- 24
- Registration Number
- NCT04690686
- Locations
- 🇹🇷
Acibadem Maslak Hospital, Medical Oncology Department - coordinating site, Istanbul, Sariyer, Turkey
🇹🇷Acibadem Atakent Hospital, Medical Oncology Department, Istanbul, Kucukcekmece, Turkey
🇹🇷Acibadem Altunizade Hospital, Mecical Oncology Department, Istanbul, Uskudar, Turkey
A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients
Phase 1
- Conditions
- Advanced Breast Cancer
- Interventions
- Other: Plasma soluble TNF receptor pulldown + chemotherapyOther: Plasma soluble TNF receptor pulldownDrug: Chemotherapy Drugs, Cancer
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Immunicom Inc
- Target Recruit Count
- 170
- Registration Number
- NCT04004910
- Locations
- 🇹🇷
Altunizade Acıbadem Hospital, Istanbul, Uskudar, Turkey
🇵🇱Katedra i Klinika Onkologii UJ CM, Kraków, Małopolskie, Poland
🇵🇱Centrum Medyczne INTERCOR Sp. z o.o., Bydgoszcz, Poland
© Copyright 2025. All Rights Reserved by MedPath